序号 | 专利名 | 申请号 | 申请日 | 公开(公告)号 | 公开(公告)日 | 发明人 |
---|---|---|---|---|---|---|
41 | 항생제 10381b의 제조방법 | KR1019880700236 | 1987-06-25 | KR100086561B1 | 1995-07-06 | 알렉잰더디이아르고우델리스; 프랭클린비이쉴리데이; 엘리스엘라보오드; 스콧트이이트루에스델 |
42 | 항생제LL-E19020알파및베타,그제조방법및이를이용한동물감염의방지또는조절법 | KR1019870006817 | 1987-06-30 | KR100085169B1 | 1995-05-24 | 가이토마스카아터; 마이클그린슈타인; 조지프제이콥굿맨; 도널드브루스보더즈; 윌리엄마이클메이즈; 레이몬드토마스테스타; 어윈보이든웃드; 메리율러즈도우셔; 시드니캔터; 로버트리이케닛트쥬니어 |
43 | 아릴 에탄올 아민이의 제조 방법 및 생산 촉진을 위한 이의 용도 | KR1019870010100 | 1987-09-11 | KR1019880003963A | 1988-05-31 | 한스린델; 베르너할렌바흐; 프리드리히베르샤우어; 안노데정; 마틴쉬어 |
내용 없음 | ||||||
44 | 글리코펩타이드 바이오컨버전 생성물의 제조방법 | KR1019840006507 | 1984-10-19 | KR100022735B1 | 1987-01-30 | 글래디스마리클렘; 래번드와인보에크; 마리테레세앤더슨; 카알해인즈마이클 |
45 | 신규 글라이코펩타이드 유도체의 제조방법 | KR1019840006506 | 1984-10-19 | KR100022734B1 | 1987-01-30 | 로버트마이클몰리; 매뉴엘데보노 |
46 | 신규 글라이코펩타이드 유도체의 제조방법 | KR1019840006506 | 1984-10-19 | KR1019860001290B1 | 1986-09-10 | 로버트마이클몰리; 매뉴엘데보노 |
New glycopeptide derivs. of formula (I) [W=residue of glycopeptide antibiotic of formula(II) and selected from A35512 factors A,B,C,E, and H A35512B pseudoaglycone, actaplanin factors A,B1,B2, B3,C1a,C2aC3,D1,D2,E1,G,K,L,M,N and O, actaplanin pseudoaglycone, A41030 factors A,B,C,D,E,F and G, A47934, restocetin A and ristocetin A pseudoaglycone! and their salts were prepd. by oxidative deamination of A35512 or actaplanin factors etc. Method comprises reacting the artibiotics in a polar solvent in the presence of an oxidizing agent until the antibiotic is diaminated to give formula(I) . (I) are active against Gram-positive bacteria and are useful in aminal feeds for increasing utilization. | ||||||
47 | 글리코펩타이드 바이오컨버전 생성물의 제조방법 | KR1019840006507 | 1984-10-19 | KR1019850003411A | 1985-06-17 | 글래디스마리클렘; 래번드와인보에크; 마리테레세앤더슨; 카알해인즈마이클 |
내용없음 | ||||||
48 | N-아실 글리코펩타이드 유도체의 제조방법 | KR1019840006505 | 1984-10-19 | KR1019850003409A | 1985-06-17 | 매뉴엘데보노 |
내용없음 | ||||||
49 | 프레우로무티린 글리코사이드 유도체의 제조방법 | KR1019780003347 | 1978-11-07 | KR100011706B1 | 1982-03-31 | 라마크라쉬난나라잔 |
50 | 포티마이신 B의 제조 방법 | KR1019740000432 | 1974-01-01 | KR100006538B1 | 1979-07-11 | 나라다까시; 다까자와세이고; 오까찌로; 가와모도이사오; 야마모도미쯔요시 |
51 | 반추동물사료용 항생물질의 제조방법 | KR1019720001926 | 1972-12-12 | KR1019780000249B1 | 1978-07-06 | |
52 | FOXM1 MODULATORS AND USES THEREOF | PCT/US2017/044834 | 2017-08-01 | WO2018026776A3 | 2018-02-08 | JONES, Jeremy; OTTO-DUESSEL, Maya |
Disclosed herein, inter alia, are FOXMl modulators and methods for modulating the activity of androgen receptors in neuronal cells to treat various diseases, such as spinal-bulbar muscular atrophy, amyotrophic lateral sclerosis, and Alzheimer's disease. |
||||||
53 | IBS MICROBIOTA AND USES THEREOF | PCT/US2015/029040 | 2015-05-04 | WO2015171493A1 | 2015-11-12 | GOLDEN, Pam; FODOR, Anthony; BORTEY, Enoch; FORBES, William |
The instant application provides methods of diagnosing and treating a subject having IBS. In certain embodiments, the methods also include diagnosing subjects who will respond to IBS treatment with rifaximin. The methods include determining the identity and prevalence of the bacterial community in the gastrointestinal (Gl) tract. In certain embodiments, the microbiome comprises the Gl tract microbiome. In certain embodiments, the microbiome comprises the Gl tract bacterial population. In certain embodiments, the microbiome comprises stool bacterial. The methods include analysis of the identity of the bacterial community in the gastrointestinal (Gl) microbiome to produce a profile of diversity of the bacterial communities. |
||||||
54 | IMPROVED TREATMENT FOR ADENOID CYSTIC CARCINOMA | PCT/SE2014/050140 | 2014-02-04 | WO2014123476A1 | 2014-08-14 | STENMAN, Göran; ANDERSSON, Mattias |
The present application relates to inhibitors of epidermal growth factor receptor (EGFR) kinase, MET kinase, insulin receptor (IR) kinase and insulin-like growth factor 1 (IGF1 R) kinase for use in the treatment of neoplastic disease such as adenoid cystic carcinoma (ACC) and dermal cylindroma characterized by MYB activation. |
||||||
55 | 用于富集、提纯干细胞的方法、试剂盒及其应用方法 | PCT/CN2012/083545 | 2012-10-26 | WO2013060282A1 | 2013-05-02 | 卢磊磊; 李福生; 卢淼淼; 卢晶晶 |
提供了一种用于富集、提纯干细胞的方法、试剂盒及其应用方法。该方法、试剂盒可直接用于啮齿动物、人类或其他哺乳动物来源的干细胞富集提纯,采用该方法、试剂盒可有效且精准地从所述细胞群中富集、提纯出干细胞;此外,根据该方法、试剂盒获得的干细胞还可以不带任何外来标记,该试剂盒具有使用简捷、可工业化生产、实用有效的优点。还提供了获得的干细胞及其在诸如研究、诊断、药物筛选或治疗中的用途。 |
||||||
56 | CONTROLLED-RELEASE ANTIBIOTIC NANOPARTICLES FOR IMPLANTS AND BONE GRAFTS | PCT/US2011042776 | 2011-07-01 | WO2012003432A3 | 2012-03-01 | GILES PATTY-FU |
The present invention relates to the preparation and use of antibiotic-containing nanoparticles for coating an implant including cranial implants and bone graft sites to provide the extended release of antibiotics to treat infection. | ||||||
57 | グリコペプチド抗生物質配糖化誘導体 | PCT/JP2008/073511 | 2008-12-25 | WO2009081958A1 | 2009-07-02 | 松井 耕平; 皆川 和之; 吉田 修; 森元 健次; 緒方 雄貴 |
本発明は新規なグリコペプチド抗生物質誘導体を提供する。 これらのグリコペプチド抗生物質誘導体は、式: (式中、nは、1~5の整数;Sugはそれぞれ独立して単糖であり、(Sug)n は、同一または異なる1~5個の単糖が結合して形成される2価の糖残基;RA1は、置換されていてもよい低級アルキル、置換されていてもよい低級アルケニル、または置換されていてもよいシクロアルキル;REは、OHまたはNHAc(Acはアセチル))で示される糖残基(I)が、グリコペプチド骨格内の4番目のアミノ酸残基の芳香環に結合していることを特徴とする。これらの誘導体は、バンコマイシン耐性の細菌に対する抗菌活性を有する。 |
||||||
58 | TRIAZOLE-BASED AMINOGLYCOSIDE-PEPTIDE CONJUGATES AND METHODS OF USE | PCT/IB2008/003486 | 2008-05-28 | WO2009037592A2 | 2009-03-26 | SCHWEIZER, Frank; ZHANEL, George, G.; BERA, Smritilekha |
Aminoglycoside-amino acid and -peptide conjugates comprising a triazolyl linker are provided along with efficient methods of their preparation. The aminoglycoside may be an aminoglycoside antibiotic. Conjugates comprising an aminoglycoside antibiotic may exhibit antimicrobial activities against Gram-positive and/or Gram-negative strains and display significantly enhanced activity against multi-drug resistant MRSA and MRSE when compared to their unconjugated aminoglycoside antibiotic counterparts. |
||||||
59 | ANTIMICROBIAL AND ANTI-INFLAMMATORY THERAPIES AND COMPOSITIONS | PCT/US2008054453 | 2008-02-20 | WO2008103751A3 | 2008-12-31 | GALLO RICHARD; NIZET VICTOR; COGEN ANNA; LAI YUPING |
The disclosure provides methods and compositions useful for treating microbial and viral infections. In certain aspects, the compositions and methods relate to the use of an effective amount of a delta-haemolysin and/or phenol soluble modulin-delta or functional variant thereof. In other aspects, the compositions and methods relate to the use of an effective amount of Staphylococcus epidermidis or an extract of 5. epidermidis comprising delta-haemolysin and/or phenol soluble modulin-delta or functional variant thereof. | ||||||
60 | 抗真菌性物質 | PCT/JP2008/053574 | 2008-02-28 | WO2008105516A1 | 2008-09-04 | 岸本 憲明; 藤田 藤樹夫; 北口 佳栄; 有本 隆人; 村上 澄恵; 喜多川 雄介; 伊藤 恵美; 山口 文秀 |
本発明は、キャンディダ属菌、サッカロマイセス属菌、ピキア属菌、ロドトルラ属菌、クラビスポラ属菌、及びトルラスポラ属菌からなる群より選ばれる1の酵母が産生する、胞子の発芽を阻害する抗真菌性物質、及び、下記の特徴を有する抗真菌性物質に係る発明である;1)pH7.0において、抗真菌活性を有すること、2)10%(w/w)スキムミルク培地で前記酵母を培養した培養液が、抗真菌活性を有すること、3)10%(w/w)スキムミルク培地で前記酵母を培養した培養液の上清を、MWCO(Molecular Weight Cut Off、分画分子量)が10kDである限外濾過膜を用いて限外濾過した場合に、限外濾過膜表面に保持されること。 |